Antitumor Activity of AZD0754, a dnTGFβRII-Armored, STEAP2-Targeted CAR-T Cell Therapy, in Prostate Cancer

Studies revealed that six-transmembrane epithelial antigen of prostate-2 (STEAP2) was a prevalent prostate cancer antigen that displayed high, homogeneous cell surface expression across all stages of disease with limited distal normal tissue expression.
[Journal Of Clinical Investigation]
Full ArticleGraphical Abstract

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News